Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (6089)	4/4/2002 3:14:27 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Bernard, The CIPH ovarian ca test was based on a number of (as yet unknown) proteins whose combined pattern of expression allows you to discriminate between ca and non-ca. At this point they have no idea of what the actual proteins are - basically all they know is their molecular weight and the fact that they stuck to the particular substrate they were using for their chip. Please note that CIPH very likely does not have the rights to use their chips in clinical screening - they have only rights in drug discovery and "life sciences." Peter